As advised via Pharmac Tender announcement 31 March 2017 there is to be a change in the listing and future HML Status.

New listing from 1 March 2018 – Piperacillin with Tazobactum Sandoz.

The incumbent brand Hospira will be deleted from the HML effective from 1 May 2018.

On that basis we would recommend you continue to purchase the incumbent and we will change automatically no later than 1 April 2018 or as soon as existing stocks are depleted.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

We thank you in anticipation of your ongoing support.



About The Author